SLC25A17: A Potential Drug Target and Biomarker for Mitochondrial Carrier protein

Target Name: SLC25A17

NCBI ID: G10478

SLC25A17

SLC25A17: A Potential Drug Target and Biomarker for Mitochondrial Carrier protein

Abstract:

SLC25A17, a member of the SLC25 family, is a protein expressed in the mitochondria that plays a crucial role in the transport of various molecules across the inner mitochondrial membrane. The peroxisomal membrane protein, known as P-PMP, is a 34kDa protein that is also expressed in the peroxisomes, which are small organelles found in the cytoplasm of eukaryotic cells. SLC25A17 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

Introduction:

Mitochondria are organelles located in the cytoplasm of eukaryotic cells that are responsible for generating energy through a process called cellular respiration. The mitochondria also play a crucial role in the production of various molecules that are essential for cellular function and homeostasis. Peroxisomes are small organelles that are found in the cytoplasm of eukaryotic cells and are responsible for the production and delivery of various molecules to the mitochondria.

SLC25A17 is a protein expressed in the mitochondria that is involved in the transport of various molecules across the inner mitochondrial membrane. It is a member of the SLC25 family, which includes several other proteins that are involved in the transport of various molecules across the membrane, including SLC25A16 and SLC25A20. P-PMP, also known as peroxisomal membrane protein, is a 34kDa protein that is also expressed in the peroxisomes.

SLC25A17 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its role in these diseases is still being investigated, but its potential as a drug target is significant.

Drug Target Potential:

SLC25A17 has been shown to play a role in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its potential as a drug target is based on its involvement in the transport of various molecules across the inner mitochondrial membrane and its expression in the peroxisomes.

SLC25A17 has been shown to be involved in the transport of chemotherapy drugs to the mitochondria, which can increase the drug sensitivity of cancer cells. Additionally, SLC25A17 has been shown to be involved in the transport of neurotransmitters, such as dopamine and serotonin, which are involved in various neurological disorders. Therefore, SLC25A17 may be a potential drug target for neurodegenerative disorders.

SLC25A17 has also been shown to be involved in the transport of cardiovascular risk factors, such as low density lipoprotein (LDL) cholesterol, which is a major risk factor for cardiovascular disease. Therefore, SLC25A17 may also be a potential drug target for cardiovascular disease.

Biomarker Potential:

SLC25A17 has been shown to be involved in various diseases, including cancer, neurodegenerative disorders, and cardiovascular disease. Therefore, it has the potential to serve as a biomarker for these diseases.

SLC25A17 has been shown to be involved in the transport of chemotherapy drugs to the mitochondria, which can increase the drug sensitivity of cancer cells. Therefore, SLC25A17 may be used as a biomarker for cancer,

Protein Name: Solute Carrier Family 25 Member 17

Functions: Peroxisomal transporter for multiple cofactors like coenzyme A (CoA), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and nucleotide adenosine monophosphate (AMP), and to a lesser extent for nicotinamide adenine dinucleotide (NAD(+)), adenosine diphosphate (ADP) and adenosine 3',5'-diphosphate (PAP). May catalyze the transport of free CoA, FAD and NAD(+) from the cytosol into the peroxisomal matrix by a counter-exchange mechanism

The "SLC25A17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets